9 
section on roles and responsibilities needs strengthening. This will be 
discussed tomorrow morning. 
As all of you are aware, there have been legislative developments in 
the past year on this subject. Upon the recommendations of the Federal 
Interagency Committee, Secretary Califano had legislation developed and 
an Administration bill was introduced into the Congress. Hearings were held 
on this bill and several others, but no legislation came out of the past 
session of the Congress. In the absence of legislation, all federally 
funded recombinant DNA research is being conducted under the NIH standards 
as currently agreed upon by all the agencies involved. In the private sector 
where work is not publicly funded, the pharmaceutical manufacturers, for 
example, have publicly given their assurance of voluntary compliance with 
the Guidelines. 
Recombinant DNA research is also being conducted in many countries of 
the world. Many national and international bodies have reviewed this sub- 
ject. The international aspects of the research have been analyzed in the 
report by the Interagency Committee — the Blue Book, to which I just referred. 
The report notes, for example, that the United Kingdom and Canada have also 
issued guidelines that differ somewhat in detail but are similar concep- 
tually to those of NIH, and there are emerging other national versions of 
guidelines . 
We are honored to have with us today a number of distinguished interna- 
tional participants in this discussion. I have already introduced Sir John 
Kendrew, who is serving on the Committee. At this time I would also like to 
introduce Dr. David Suzuki. Dr. Suzuki, were you able to make it? He was 
ill yesterday. 
DR. MC CARTHY : We received a telegram that he is on his way. 
DR. FREDRICKSON: Dr. Suzuki is a Professor of Genetics at the University 
of British Columbia, and the host of Science Magazine of the Canadian Broad- 
casting Corporation, and he has a long interest in this matter. 
Other observers here include Dr. William Whelan, who is not from abroad, 
but from America, but who is Chairman of the Committee on Genetic Experimen- 
tation, so-called COGENE, which is a scientific committee of the International 
Council of Scientific Unions. 
Dr. John Tooze — good morning. And Dr. Whelan is there too, with Dr. 
Tooze. Dr. Tooze is Executive Secretary of the Liaison Committee on Recom- 
binant DNA of the European Science Foundation. Also we welcome Dr. Jan 
Zelinka. Good morning. Dr. Zelinka is the Director of the Institute of 
Molecular Biology in Bratislava, Czechoslovakia. 
Recombinant DNA techniques and the policies governing their use can 
serve, for good or for bad, as a case model for public and scientific 
[ 213 ] 
